| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Cai,Zheng-Hong | Chairman | 59.60% | Orient Europharma Co., Ltd. |
| Huang,Wen-Hong | Director | 59.60% | Orient Europharma Co., Ltd. |
| Li,Yu-Ling | Director | 59.60% | Orient Europharma Co., Ltd. |
| Song,Quan-Feng | Director | 0.20% | ZHONG LUN DEVELOPMENT CO., LTD. |
| Gao,Wei-Chao | Director | 4.61% | Santos Hotel Co., Ltd. |
| Cai,Meng-Lin | Director | 0.38% | |
| Chen,Tai-Ming | Independent Director | 0.00% | |
| Kang,Zhao-Zhou | Independent Director | 0.00% | |
| Zhang,Jia-Wen | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 316,902 | 1,222,816 | 889,912 |
| Operating cost | 151,680 | 571,257 | 421,245 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 165,222 | 651,559 | 468,667 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 165,222 | 651,559 | 468,667 |
| Operating expenses | 104,018 | 493,645 | 444,349 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 61,204 | 157,914 | 24,318 |
| Non-operating income and expenses | 2,010 | 5,209 | -1,394 |
| Net profit (loss) before tax | 63,214 | 163,123 | 22,924 |
| Income tax expense (benefits) | 12,643 | 55,749 | 636 |
| Net profit (loss) of ongoing business for the current period | 50,571 | 107,374 | 22,288 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 50,571 | 107,374 | 22,288 |
| Other comprehensive profit (loss), net | 1,131 | 9,718 | -222 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 51,702 | 117,092 | 22,066 |
| Net profit (loss) attributable to owners of parent company | 50,571 | 107,374 | 22,288 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | 51,702 | 117,092 | 22,066 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | 0 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 126,306 | 197,014 | -102,993 |
| Net cash inflows (outflows) from investing activities | 11,023 | -22,475 | -88,015 |
| Net cash inflow (outflow) from financing activities | -21,077 | -173,363 | 197,897 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1 | - | 0 |
| Increase (decrease) in cash and cash equivalents in the current period | 116,253 | 1,176 | 6,889 |
| Beginning balance of cash and cash equivalents | 84,495 | 83,319 | 76,430 |
| Ending balance of cash and cash equivalents | 200,748 | 84,495 | 83,319 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 786,897 | 728,426 | 622,252 |
| Non-current asset | 1,750,192 | 1,792,156 | 1,940,422 |
| Total asset | 2,537,089 | 2,520,582 | 2,562,674 |
| Current liability | 464,859 | 487,250 | 563,354 |
| Non-current liability | 232,944 | 245,748 | 328,828 |
| Total liability | 697,803 | 732,998 | 892,182 |
| share capital | 2,230,351 | 2,230,351 | 2,230,351 |
| Equity - secruity token | - | - | - |
| capital reserve | 1,130,328 | 1,130,328 | 1,130,328 |
| retained earning | -1,528,571 | -1,579,142 | -1,686,359 |
| Other equity | 7,178 | 6,047 | -3,828 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,839,286 | 1,787,584 | 1,670,492 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,839,286 | 1,787,584 | 1,670,492 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 8 | 8 | 7 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 113年抗藥性菌株治療用藥 | 衛生福利部屏東醫院 | 113/05/21 | 1440000.0 | 是 |
| 藥品8項單價開口契約 | 臺北榮民總醫院 | 112/11/29 | 是 | |
| Topiramate XR ER cap 50mg單價開口契約 | 臺北榮民總醫院 | 112/11/28 | 是 | |
| 藥品 | 國立成功大學醫學院附設醫院 | 112/11/24 | 11493520.0 | 是 |
| 113-114年臺北榮民總醫院分院藥品單價開口契約 | 臺北榮民總醫院 | 112/11/10 | 是 | |
| NTUH-P11303藥品招標案 | 國立臺灣大學醫學院附設醫院 | 112/10/26 | 是 | |
| 妥偏停持續性釋放膠囊25毫克(或同等品) | 國防醫學院 | 112/10/19 | 516360.0 | 是 |
| 113-114年藥品單價開口契約 | 臺北榮民總醫院 | 112/09/15 | 是 | |
| Vancomycin | 國立成功大學醫學院附設醫院 | 112/09/12 | 210000.0 | 是 |
| 藥品一批單價合約 | 國立臺灣大學醫學院附設醫院 | 112/09/05 | 是 | |
| 常備藥品7項單價開口契約 | 臺中榮民總醫院 | 112/08/23 | 是 | |
| 藥品23項(開口契約) | 高雄榮民總醫院 | 111/12/12 | 是 | |
| 抗結核新藥臨床試驗(試驗編號NDMCHUEXC030TB1)委託執行服務 | 國防醫學院 | 105/12/08 | 3800000.0 | 是 |
| 白蛋白注射液招標 | 臺北市立聯合醫院 | 105/09/21 | 是 | |
| 臨購藥品乙批 | 衛生福利部臺北醫院 | 105/09/20 | 否 | |
| NORMAL SERUM ALBUMIN 20% 50ML一批 | 臺中榮民總醫院 | 105/06/21 | 是 | |
| 抗結核新藥臨床試驗(試驗編號 NDMC HUEXC030TB1)委託執行服務 | 國防醫學院 | 105/03/17 | 6770000.0 | 是 |
| 臨床第二期第三期試驗-藥動試驗部份 | 國防醫學院 | 103/11/19 | 4400100.0 | 是 |
| 抗結核新藥臨床試驗(試驗編號NDMC HUEXC030TB1)委託執行服務 | 國防醫學院 | 103/06/12 | 6850000.0 | 是 |
| 第三代MVA天花疫苗 | 國防醫學院 | 102/09/04 | 292500.0 | 是 |
